Evidence map›Paper›PMID 28548128›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2017

Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.

Gregor Krings, Nancy M Joseph, Gregory R Bean, David Solomon, Courtney Onodera, Eric Talevich, Iwei Yeh, James P Grenert, Elizabeth Hosfield, Emily D Crawford and 5 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Molecular Basis of Breast Tumor Heterogeneity.Advances in experimental medicine and biology · 2025
    Review
  8. Article
  9. Breast Cancer Histopathology in the Age of Molecular Oncology.Cold Spring Harbor perspectives in medicine · 2024
    Review
  10. Article
  11. Article
  12. Phase separation underlies signaling activation of oncogenic NTRK fusions.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  13. Secretory Breast Carcinoma: Report of Two Cases and Literature Review.Clinical medicine insights. Case reports · 2023
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Gregor KringsDepartment of Pathology, University of California San Francisco (UCSF), San Francisco, CA, USA.
Nancy M JosephDepartment of Pathology, University of California San Francisco (UCSF), San Francisco, CA, USA.
Gregory R BeanDepartment of Pathology, University of California San Francisco (UCSF), San Francisco, CA, USA.
David SolomonDepartment of Pathology, University of California San Francisco (UCSF), San Francisco, CA, USA.
Courtney OnoderaDepartment of Pathology, University of California San Francisco (UCSF), San Francisco, CA, USA.
Eric TalevichDepartment of Pathology, University of California San Francisco (UCSF), San Francisco, CA, USA.
Iwei YehDepartment of Dermatology, University of California San Francisco (UCSF), San Francisco, CA, USA.
James P GrenertDepartment of Pathology, University of California San Francisco (UCSF), San Francisco, CA, USA.
Elizabeth HosfieldDepartment of Pathology, Kaiser Permanente, Oakland, CA, USA.
Emily D CrawfordDepartment of Biochemistry and Biophysics, University of California San Francisco (UCSF), San Francisco, CA, USA.
Richard C JordanDepartment of Dermatology, University of California San Francisco (UCSF), San Francisco, CA, USA.
Annemieke van ZanteDepartment of Pathology, University of California San Francisco (UCSF), San Francisco, CA, USA.
Charles ZaloudekDepartment of Pathology, University of California San Francisco (UCSF), San Francisco, CA, USA.
Sandra J ShinDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Yunn-Yi ChenDepartment of Pathology, University of California San Francisco (UCSF), San Francisco, CA, USA.
University of California, San Francisco · USCornell University · USKaiser Permanente · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secretory carcinomas of the breast are rare tumors with distinct histologic features, recurrent t(12;15)(p13;q25) translocation resulting in ETV6-NTRK3 gene fusion and indolent clinical behavior. Mammary analog secretory carcinomas arising in other sites are histopathologically similar to the breast tumors and also harbor ETV6-NTRK3 fusions. Breast secretory carcinomas are often triple (estrogen and progesterone receptor, HER2) negative with a basal-like immunophenotype. However, genomic studies are lacking, and whether these tumors share genetic features with other basal and/or triple negative breast cancers is unknown. Aside from shared ETV6-NTRK3 fusions, the genetic relatedness of secretory carcinomas arising in different sites is also uncertain. We immunoprofiled and sequenced 510 cancer-related genes in nine breast secretory carcinomas and six salivary gland mammary analog secretory carcinomas. Immunoprofiles of breast and salivary gland secretory carcinomas were similar. All the tumors showed strong diffuse MUC4 expression (n=15), and SOX10 was positive in all nine breast and in five out of six salivary gland tumors. All breast secretory carcinomas were triple negative or weakly ER-positive, and all tumors at both the sites expressed CK5/6 and/or EGFR, consistent with a basal-like phenotype. Sequencing revealed classic ETV6-NTRK3 fusion genes in all cases, including in carcinoma in situ of one breast tumor. Translocations were reciprocal and balanced in six out of nine breast and three out of six salivary gland tumors and were complex in three others. In contrast to most breast basal carcinomas, the mutational burden of secretory carcinomas was very low, and no additional pathogenic aberrations were identified in genes typically mutated in breast cancer. Five (56%) breast and two (33%) salivary gland tumors had simple genomes without copy number changes; the remainder had very few changes, averaging 1.3 per tumor. The ETV6-NTRK3 derivative chromosome was duplicated in one breast and one salivary gland tumor, and was the only copy number change in the latter. The findings highlight breast secretory carcinoma as a subtype more closely related to mammary analog secretory carcinoma than to basal/triple negative breast cancers of no special type. Lack of pathogenic mutations in common cancer-related genes suggests that ETV6-NTRK3 alone may suffice to drive these tumors and likely helps explain their indolent behavior.

Indexed as

AdolescentAdultAgedBiomarkers, TumorBreast NeoplasmsETS Translocation Variant 6 ProteinFemaleGene Expression ProfilingHumansMaleMammary Analogue Secretory CarcinomaMiddle AgedOncogene Proteins, FusionReceptor, trkCSalivary Gland NeoplasmsYoung AdultBiomarkers, TumorETS Translocation Variant 6 ProteinETV6-NTRK3 fusion protein, humanOncogene Proteins, FusionReceptor, trkC

Identifiers

PMID28548128
OpenAlexW2619024101

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.